<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2021.111001</article-id><article-id pub-id-type="publisher-id">MD-40812</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20210100000_75140102.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  运用完全置入式静脉输液港的并发症及原因分析
  The Analysis of Complications of Totally Implantable Venous Access Devices
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>宸君</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>越</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>学君</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>昆明市第一人民医院乳腺科，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>1</fpage><lpage>7</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：分享我科静脉输液港使用经验，探讨置入式静脉输液港并发症及其原因。方法：回顾性分析我科2011~2017年运用静脉输液港进行乳腺癌化疗患者相关并发症，探讨发病原因及防治方法。结果：乳腺癌化疗患者共130名放置静脉输液港，共发生并发症9例(6.9%)，其中3例(2.3%)发生导管相关的血栓，1例(0.8%)导管头移位，1例(0.8%)静脉港座外露，2例(1.5%)导管脱落，2例(1.5%)放置失败。结论：静脉港是安全有效的治疗手段，其并发症发生率较低。无菌原则和医生及护理人员规范的操作可有效的减少并发症发生率。
   Objective: To present our experience and clarify the complications of totally implantable venous access ports (TIVAP) and the risk factors for such complications. Methods: To analyze the compli-cations of breast cancer patients in our center who implanted TIVAP for chemotherapy from 2011 to 2017 and to explore the causes and methods of prevention and treatment. Result: There were 130 patients with breast cancer placed TIVAP, Thrombotic complications in 3 cases (2.3%), catheter migration in 1 case (0.8%), base of the port exposure in 1 case (0.8%), pinch-off syndrome in 2 cases (1.5%), failure of placement in 2 cases (1.5%). Conclusion: TIVAP is a safe procedure with lower complications, health care workers involved doctors and nurses should be aware of septic principles, careful insertion and skilled management which would decrease the complication incidence.
 
</p></abstract><kwd-group><kwd>完全置入式静脉港，并发症，乳腺癌, Totally Implantable Venous Access Ports</kwd><kwd> Complication</kwd><kwd> Breast Cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分享我科静脉输液港使用经验，探讨置入式静脉输液港并发症及其原因。方法：回顾性分析我科2011~2017年运用静脉输液港进行乳腺癌化疗患者相关并发症，探讨发病原因及防治方法。结果：乳腺癌化疗患者共130名放置静脉输液港，共发生并发症9例(6.9%)，其中3例(2.3%)发生导管相关的血栓，1例(0.8%)导管头移位，1例(0.8%)静脉港座外露，2例(1.5%)导管脱落，2例(1.5%)放置失败。结论：静脉港是安全有效的治疗手段，其并发症发生率较低。无菌原则和医生及护理人员规范的操作可有效的减少并发症发生率。</p></sec><sec id="s2"><title>关键词</title><p>完全置入式静脉港，并发症，乳腺癌</p></sec><sec id="s3"><title>The Analysis of Complications of Totally Implantable Venous Access Devices<sup> </sup></title><p>Chenjun Guo, Yue Yang<sup>*</sup>, Xuejun Guo</p><p>Galactophore Department, The First Hospital of Kunming, Kunming Yunnan</p><p><img src="//html.hanspub.org/file/1-2170278x5_hanspub.png" /></p><p>Received: Dec. 22<sup>nd</sup>, 2020; accepted: Feb. 26<sup>th</sup>, 2021; published: Mar. 5<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/1-2170278x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To present our experience and clarify the complications of totally implantable venous access ports (TIVAP) and the risk factors for such complications. Methods: To analyze the complications of breast cancer patients in our center who implanted TIVAP for chemotherapy from 2011 to 2017 and to explore the causes and methods of prevention and treatment. Result: There were 130 patients with breast cancer placed TIVAP, Thrombotic complications in 3 cases (2.3%), catheter migration in 1 case (0.8%), base of the port exposure in 1 case (0.8%), pinch-off syndrome in 2 cases (1.5%), failure of placement in 2 cases (1.5%). Conclusion: TIVAP is a safe procedure with lower complications, health care workers involved doctors and nurses should be aware of septic principles, careful insertion and skilled management which would decrease the complication incidence.</p><p>Keywords:Totally Implantable Venous Access Ports, Complication, Breast Cancer</p><disp-formula id="hanspub.40812-formula2"><graphic xlink:href="//html.hanspub.org/file/1-2170278x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2170278x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2170278x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>完全置入式静脉输液港(TIVAP, totally implantable venous access ports)自1982年 [<xref ref-type="bibr" rid="hanspub.40812-ref1">1</xref>] 首次在肿瘤治疗中被提及使用至今超过30年，其优于传统输液方式、其他现代化疗通道的优势在于它可以减少肿瘤患者化疗中的不适、焦虑、疼痛及局部反复穿刺及肿瘤相关的并发症的发病率 [<xref ref-type="bibr" rid="hanspub.40812-ref2">2</xref>]。在如今的乳腺癌治疗中，静脉港已是规范、有效的治疗手段之一，由于云南地区经济发展水平落后，地方医疗政策特殊等原因，我科在2011年才成为云南省首批使用静脉输液港治疗乳腺癌的医疗机构。</p></sec><sec id="s6"><title>2. 资料、方法及数据</title><sec id="s6_1"><title>2.1. 资料</title><p>回顾性分析昆明乳腺病中心乳腺癌化疗患者共130例，年龄27~65岁，均为经颈内静脉置入静脉输液港，分别为新辅助化疗25例，术后辅助化疗87例及解救化疗18例患者。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>A. 术前向患者及家属告知静脉港放置相关并发症，取得知情告知同意书。</p><p>B. 血常规、凝血功能、胸片(或CT检查)检查无手术禁忌。</p><p>C. 枕垫肩部取仰卧头低位，头偏向对侧(选择健侧置入穿刺)，术前做胸锁乳突肌、锁骨、穿刺点及静脉港囊袋体表标记，常规消毒铺单，利多卡因麻醉成功后，超声引导下放置导丝及导管。锁骨下两横指做静脉港座囊袋，皮下组织厚0.5~1.0 cm，隧道针打通皮下导管隧道后引导导管链接静脉港座，安置导管锁扣，10 ml注射器脉冲式肝素盐水冲管封港，缝合皮肤。手术操作时间40~60分钟，置港后行胸部X线检查查看导管头位置(位于胸5~8椎体水平为宜)，当天或术后一天给予化疗治疗。蝶翼针使用限期为7天。</p></sec><sec id="s6_3"><title>2.3. 数据</title><p>共有130例静脉输液港置入患者，共9例发生并发症，统计结果如表1所示。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of complications in different subgroup</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >按化疗种类</th><th align="center" valign="middle" >总例数</th><th align="center" valign="middle" >并发症例数</th></tr></thead><tr><td align="center" valign="middle" >新辅助化疗</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >辅助化疗</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >解救化疗</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >按年龄</td><td align="center" valign="middle" >总例数</td><td align="center" valign="middle" >并发症例数</td></tr><tr><td align="center" valign="middle" >&lt;60岁</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >7</td></tr><tr><td align="center" valign="middle" >&gt;60岁</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle"  colspan="3"  >实际频数小于5，连续校正卡方检验p = 0.655，p &gt; 0.05</td></tr><tr><td align="center" valign="middle" >按位置</td><td align="center" valign="middle" >总例数</td><td align="center" valign="middle" >并发症例数</td></tr><tr><td align="center" valign="middle" >经左颈内静脉</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >经右颈内静脉</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle"  colspan="3"  >实际频数小于5，连续校正卡方检验p = 0.584，p &gt; 0.05</td></tr></tbody></table></table-wrap><p>表1. 各个亚组的并发症对比</p><p>以年龄及不同位置穿刺置管为条件对130例患者的并发症进行统计学分析，统计结果如表2所示。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Complications of totally implantable venous access device</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >早期并发症</th><th align="center" valign="middle" >2</th><th align="center" valign="middle" >占总例数百分比(%)</th></tr></thead><tr><td align="center" valign="middle" >置港失败</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.5</td></tr><tr><td align="center" valign="middle" >晚期并发症</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >5.3</td></tr><tr><td align="center" valign="middle" >导管相关血栓</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.3</td></tr><tr><td align="center" valign="middle" >导管异位</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.8</td></tr><tr><td align="center" valign="middle" >港座外露</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.8</td></tr><tr><td align="center" valign="middle" >导管脱落</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.5</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >6.9</td></tr></tbody></table></table-wrap><p>表2. 完全置入式静脉港并发症</p></sec><sec id="s6_4"><title>2.4. 相关图片</title><p>130例患者中有2例静脉港导管发生脱落，CT检查如图1、图2所示。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>共有130例静脉输液港置入患者，共9例发生并发症(表1)。其中在放置初期2例(1.5%)静脉港放置失败案例后，使用超声实时引导放置静脉港导管，未出现失败及气胸、误穿动脉、血肿患者。其中有3例(2.3%)导管相关血栓患者(2例导管内血栓及1例颈内静脉血栓)，导管内血栓经尿激酶冲管后再通，之后反复血栓形成遂取出静脉港；颈内静脉血栓患者出现颈部软组织肿胀后使用华法令联合阿司匹林及氯吡格雷交替治疗1月后，血栓消失，继续使用静脉港至化疗结束。1例(0.8%)静脉港底座外露于皮肤，遂取出后缝合破损口，顺利愈合。1例(0.8%)患者置港后1月导管头移位至锁骨下静脉，患者要求取出静脉港。2例(1.5%)静脉港导管发生脱落，1例为术后50天发生心悸、胸闷后行胸片检查提示导管异位，CT</p><p>图1. 导管脱落入右心室</p><p>图2. 导管脱落入肺静脉</p><p>检查提示导管位于右肺静脉内(见图2)。经介入捕捞自股静脉取出导管，同时取出静脉港，经抗凝治疗后无不良后果；1例患者有房颤病史，术后120天静脉港冲管护理时发现导管不通畅，遂行CT检查提示患者导管位脱落位于上腔静脉内(见图1)，无自觉症状，遂介入捕捞并取出静脉港后经抗凝治疗后，无不良后果。以年龄及不同位置穿刺置管为条件对130例患者的并发症进行统计学分析(表2)，结果无明显统计学差异，即年龄及穿刺部位不是并发症发生的单发高危因素。因样本量较小，未对并发症亚组间进行统计学分析。</p></sec><sec id="s8"><title>4. 讨论</title><p>静脉港的并发症按时间分为早期(放置时)及晚期(使用护理过程中)并发症。我中心在初期使用“盲穿”方法放置导管发生穿刺失败2个案例后改用超声实时引导穿刺，提高穿刺成功率避免反复穿刺 [<xref ref-type="bibr" rid="hanspub.40812-ref3">3</xref>]，未出现血肿、误穿动脉、气胸的病例。血肿多为止血不佳造成，可在制作囊袋时使用纱条填塞加压止血，必要时结扎或电凝充分止血。形成血肿后可抽吸积血同时使用硫酸镁湿敷治疗。文献报道 [<xref ref-type="bibr" rid="hanspub.40812-ref4">4</xref>] 体型宽短及身高较矮的患者当导丝过深可引起心率失常，故超声引导能尽量减少这一并发症的发生。</p><p>在静脉港留置过程中，最常见的是栓塞及感染最为常见。栓塞中有血栓性及非血栓性。非血栓性可能有机械原因、药物沉积等引起 [<xref ref-type="bibr" rid="hanspub.40812-ref5">5</xref>]，其中我中心2例患者为导管相关性栓子，可为非血栓性，可能为纤维蛋白鞘形成而使导管堵塞，文献报道 [<xref ref-type="bibr" rid="hanspub.40812-ref6">6</xref>] 纤维蛋白鞘在24小时内形成，7天内覆盖于整个导管壁，导致导管堵塞，利用尿激酶溶栓后可再次发生；但不除外导管内小血栓形成可能。1例患者为左侧颈内静脉血栓形成，患者年龄为59岁，乳腺癌，左侧颈内静脉内径较右侧小，异物放入导管后血流动力改变，加之年龄、肿瘤、化疗治疗等均为血栓形成高危因素易形成血栓 [<xref ref-type="bibr" rid="hanspub.40812-ref7">7</xref>]，故多因素为造成此患者颈内静脉血栓发生的原因。欧洲文献对管道堵塞的报道较多，其中有前瞻性研究 [<xref ref-type="bibr" rid="hanspub.40812-ref8">8</xref>] 未给予抗凝干预，认为高龄、左侧颈内静脉或左侧锁骨下静脉穿刺、既往抗凝治疗史均为血栓形成独立高危因素。有研究以超声定期进行导管血栓监测的静脉血栓发生率可由0.3%~28%上升至27%~66% [<xref ref-type="bibr" rid="hanspub.40812-ref9">9</xref>]，所以大多血栓发生为无症状血栓。未来对留置管道的凝血功能无异常的患者进行抗凝干预可能是导管相关血栓治疗的有效方法之一。另外不同粗细的导管发生堵管几率不同，有文献 [<xref ref-type="bibr" rid="hanspub.40812-ref10">10</xref>] 建议使用 ≤ 7F的导管。聚氨酯较硅树脂材质导管易发生断裂，而反之硅树脂材质易形成纤维蛋白鞘而发生导管堵塞 [<xref ref-type="bibr" rid="hanspub.40812-ref11">11</xref>]。我中心在放置静脉港及护理过程中医护紧密合作，严格执行无菌操作，化疗后门诊建立化疗随访，对化疗患者低白细胞的干预较早，暂未发生港相关的感染事件。而国外感染事件以印度及韩国报道较多 [<xref ref-type="bibr" rid="hanspub.40812-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.40812-ref13">13</xref>]，可能与医疗环境及医疗水平及患者营养水平抵抗感染能力有关。法国有报道 [<xref ref-type="bibr" rid="hanspub.40812-ref14">14</xref>] 术后感染与术后开始使用静脉港的时间有关，我中心均为当天或术后第1天使用静脉港，期待较大样本量时可以进行对比及验证。</p><p>对1例因静脉港表面皮肤坏死而使静脉港座外露的患者，经分析可能与一下原因有关：1) 制作囊袋时预留皮下组织较薄，放置人工植入物后皮肤表面张力较大，血供差导致坏死；2) 化疗患者食欲差、恶性消耗引起体重减轻，皮下脂肪减少，局部皮肤反复摩擦造成破损外露。静脉港外露的报道以东亚、印度 [<xref ref-type="bibr" rid="hanspub.40812-ref13">13</xref>] 等发展中国家报道较欧美国家多，可能与其饮食结构及经济发展水平有关。此患者取港缝合后皮肤愈合良好，结合我中心经验，建议采用锐性分离制作囊袋，避免钝性分离造成在皮下浅层分离而造成皮下组织保留过少。</p><p>在留置静脉港时，导管移位及导管脱落是较为严重的并发症，有1例患者发生经左侧颈内静脉置管导管头移位至左侧锁骨下静脉，患者无不良反应，患者强烈要求拔除。导管脱落被Aitken and Minton [<xref ref-type="bibr" rid="hanspub.40812-ref15">15</xref>] 等首次提出称为“pinch-off sign”，发生率报道为0.6%~1.6%，多为经锁骨下静脉置管胸大肌与第1肋骨夹闭导管所致。有文献报道认为锁骨下置管的导管脱落等并发症发病率可达12% [<xref ref-type="bibr" rid="hanspub.40812-ref8">8</xref>]，目前大多数医生均采取经颈内静脉置管。Bucki [<xref ref-type="bibr" rid="hanspub.40812-ref16">16</xref>] 等报道经颈内静脉置管脱落发生率为0.7% (2/309)，Nagasawa [<xref ref-type="bibr" rid="hanspub.40812-ref17">17</xref>] 等报道概率为1.8% (1/106)，Wu [<xref ref-type="bibr" rid="hanspub.40812-ref18">18</xref>] 等报道为(1.7 %)，Seung Yeon Ko [<xref ref-type="bibr" rid="hanspub.40812-ref19">19</xref>] 等报道1例经右侧颈内静脉置管导管脱落病例，认为导管破损及不适当的链接可降低颈内静脉置管脱落的发生率。我中心数据与国外数据分析文献结合病例，考虑导管脱落原因可能有以下几点：未将导管头与导管底座链接到位；导管锁卡扣时带入少量组织，脂肪液化后影响固定效果；少量化疗药物外溢或者导管破损造成脱落；冲洗导管时压强过大引起导管脱落；患者呕吐时负压大造成导管牵拉脱落；康复训练时过度拉伸，轻者使导管异位，重者使底座上提引起导管脱落。但以上推论是否与导管断裂及脱落有直接关系有待进一步的研究和验证。</p><p>我中心数据总并发症发病率及各项并发症发病率均在国际及国内文献报道的范围内。并发症集中在晚期留置的并发症，未发生早期(血肿、气胸、心律失常等)并发症及感染、渗漏及港座反转等，而未发生早期并发症可能与超声适时引导有直接关系。</p></sec><sec id="s9"><title>5. 结论</title><p>完全式置入式静脉输液港使用安全、方便，是一种成熟的恶性肿瘤化疗输液通道，主要并发症中感染、栓塞及导管脱落发生后可能对患者的心理及生理造成严重的影响，所以医务人员对并发症的理解及防治是降低并发症的关键。但材料科学的进步以及对静脉输液港并发症的研究及问题的解决能帮助我们将并发症的发生率将至最低。静脉港将逐渐被良性疾病的治疗所逐渐接受，目前有学者 [<xref ref-type="bibr" rid="hanspub.40812-ref20">20</xref>] 将静脉港的放置与整形外科结合，进行皮槽制作及放置的创新，将切口尽可能的缩小。德国在2006年时已经进行4045例大样本研究使用静脉港患者的感受对静脉港治疗的影响 [<xref ref-type="bibr" rid="hanspub.40812-ref21">21</xref>]，我们也将更加关注患者在使用过程中的心理状态，未来静脉港的使用将会更加普及。</p></sec><sec id="s10"><title>文章引用</title><p>郭宸君,杨 越,郭学君. 运用完全置入式静脉输液港的并发症及原因分析The Analysis of Complications of Totally Implantable Venous Access Devices[J]. 医学诊断, 2021, 11(01): 1-7. https://doi.org/10.12677/MD.2021.111001</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40812-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Niederhuber, J.E., Ensminger, W., Gyves, J.W., Liepman, M., Doan, K. and Cozzi, E (1982) Totally Implanted Venous and Arterial Access System to Replace External Catheters in Cancer Treatment. Surgery, 92, 706-712.</mixed-citation></ref><ref id="hanspub.40812-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bow, E.J., Kilpatrick, M.G. and Clinch, J.J. (1999) Totally Implantable Venous Access Ports Systems for Patients Receiving Chemotherapy for Solid Tissue Malignancies: A Randomized Controlled Clinical Trial Examining the Safety, Efficacy, Costs, and Impact on Quality of Life. Journal of Clinical Oncology, 17, 1267.  
&lt;br&gt;https://doi.org/10.1200/JCO.1999.17.4.1267</mixed-citation></ref><ref id="hanspub.40812-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Yıldırım, İ., Tütüncü, A.Ç., Bademler, S., Özgür, İ., Demiray, M. and Karanlık, H. (2018) Does the Real-Time Ultrasound Guidance Provide Safer Venipuncture in Implantable Venous Port Implantation? The Journal of Vascular Access, 19, 297-302. &lt;br&gt;https://doi.org/10.1177%2F1129729817752606</mixed-citation></ref><ref id="hanspub.40812-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">刘冰, 尹杰. 完全植入式静脉输液港手术方式及并发症研究进展[J]. 中华临床医师杂志, 2014, 8(20): 3704-3708.</mixed-citation></ref><ref id="hanspub.40812-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Gonda, S.J. and Li, R. (2011) Principles of Subcuta-neous Port Placement. Vascular &amp; Interventional Radiology, 14, 198-203. &lt;br&gt;https://doi.org/10.1053/j.tvir.2011.05.007</mixed-citation></ref><ref id="hanspub.40812-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wildgruber, M., Borgmeyer, S., Haller, B., Jansen, H., Gaa, J., Kiechle, M., et al. (2015) Short-Term and Long-Term Outcome of Radiological-Guided Insertion of Central Venous Access Port Devices Implanted at the Forearm: A Retrospective Monocenter Analysis in 1704 Patients. European Ra-diology, 25, 606-616.  
&lt;br&gt;https://doi.org/10.1007/s00330-014-3417-1</mixed-citation></ref><ref id="hanspub.40812-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chang, Y.F., Lo. A.C., Tsai, C.H, Lee, P.-Y., Sun, S., Chang, T.-H., et al. (2013) Higher Complication Risk of Totally Implantable Venous Access Port Systems in Patients with Advanced Cancer—A Single Institution Retrospective Analysis. Palliative Medicine, 27, 185-191. &lt;br&gt;https://doi.org/10.1177%2F0269216311428777</mixed-citation></ref><ref id="hanspub.40812-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Voog, E., Campion, L., du Rusquec, P., Bourgeois, H., Domont, J., Denis, F., et al. (2018) Totally Implantable Venous Access Ports: A Prospective Long-Term Study of Early and Late Complications in Adult Patients with Cancer. Supportive Care in Cancer, 26, 81-89. &lt;br&gt;https://doi.org/10.1007/s00520-017-3816-3</mixed-citation></ref><ref id="hanspub.40812-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Verso, M. and Agnelli, G. (2003) Venous Thromboembolism Associated with Long-Term Use of Central Venous Catheters in Cancer Patients. Journal of Clinical Oncology, 21, 3665-3675. &lt;br&gt;https://doi.org/10.1200/JCO.2003.08.008</mixed-citation></ref><ref id="hanspub.40812-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Etezadi, V. and Trerotola, S.O. (2017) Comparison of Inversion (“Flipping”) Rates among Different Port Designs: A Single-Center Experience. CardioVascular and Inter-ventional Radiology, 40, 553-559.  
&lt;br&gt;https://doi.org/10.1007/s00270-016-1546-4</mixed-citation></ref><ref id="hanspub.40812-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Vandoni, R.E., Guerra, A., Sanna, P., Bogen, M., Cavalli, F. and Gertsch, P. (2009) Randomised Comparison of Complications from Three Different Permanent Central Venous Access Systems. Swiss Medical Weekly, 139, 313-316.</mixed-citation></ref><ref id="hanspub.40812-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Madabhavi, I., Sarkar, M., Anand, A., Panchal, H., et al. (2017) A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience. Clinical Medicine Insights: Oncology, 11, 1-6.  
&lt;br&gt;https://doi.org/10.1177%2F1179554917691031</mixed-citation></ref><ref id="hanspub.40812-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bassi, K.K., Giri, A.K., Pattanaya, M., Abraham, S.W. and Pandey, K.K. (2012) Total Implantable Venous Access Ports: Retrospective Review of Long-Term Complications in 81 Patients. India Journal of Cancer, 49, 114-118. 
&lt;br&gt;https://doi.org/10.4103/0019-509X.98934</mixed-citation></ref><ref id="hanspub.40812-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kakkos, A., Bresson, L., Hudry, D., Cousin, S., Lervat, C., Bogart, E., et al. (2017) Complication-Related Removal of Totally Implantable Venous Access Port Systems: Does the Interval between Placement and First Use and the Neutropenia-Inducing Potential of Chemotherapy Regimens Influence Their Incidence? A four-year prospective study of 4045 patients. European Journal of Surgical Oncology, 43, 689-695. 
&lt;br&gt;https://doi.org/10.1016/j.ejso.2016.10.020</mixed-citation></ref><ref id="hanspub.40812-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Aitken, D.R. and Minton, J.P. (1984) The “Pinch-Off Sign”: A Warning of Impending Problems with Permanent Subclavian Catheters. American Journal of Surgery, 148, 633-636. &lt;br&gt;https://doi.org/10.1016/0002-9610(84)90340-4</mixed-citation></ref><ref id="hanspub.40812-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Bucki, B., Tomaszewska, R., Bubała, H., Sońta-Jakimczyk, D., Karpe, J. and Stoksik, P. (2009) Application of Long term Subcutaneously Implanted Access into the Central Veins System of “PORT” Type in the Clinic of Pediatry, Pediatric Hematology and Oncology in Zabrze—15 Year Own Ob-servations. Wiadomości Lekarskie, 62, 93-98.</mixed-citation></ref><ref id="hanspub.40812-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Nagasawa, Y., Shimizu, T., Sonoda, H., Chou, H., Mekata, E. and Tani, T. (2014) Is Catheter Rupture Rare After Totally Implantable Access Port Implantation via the Right Internal Jugular Vein? Report of a Case. Surgery Today, 44, 1346-1349. &lt;br&gt;https://doi.org/10.1007/s00595-013-0631-4</mixed-citation></ref><ref id="hanspub.40812-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wu, C.Y., Fu, J.Y., Feng, P.H., Kao, T.C., Yu, S.Y., Li, H.J., et al. (2011) Catheter Fracture of Intravenous Ports and its Management. World Journal of Surgery, 35, Article No. 2403. &lt;br&gt;https://doi.org/10.1007/s00268-011-1200-x</mixed-citation></ref><ref id="hanspub.40812-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ko, S.Y., Park, S.C., Hwang, J.K. and Kim, S.D. (2016) Spon-taneous Fracture and Migration of Catheter of a Totally Implantable Venous Access Port via Internal Jugular Vein—A Case Report. Journal of Cardiothoracic Surgery, 11, Article No. 50. &lt;br&gt;https://doi.org/10.1186/s13019-016-0450-y</mixed-citation></ref><ref id="hanspub.40812-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Liberale, G. (2017) Totally Implantable Vascular Access Device (TIVAD) Placement: A Modified Technique That Takes Post-Procedure Aesthetic Aspects into Account. Supportive Care in Cancer, 25, 1137-1140. 
&lt;br&gt;https://doi.org/10.1007/s00520-016-3503-9</mixed-citation></ref><ref id="hanspub.40812-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Kreis, H., Loehberg, C.R., Lux, M.P., Ackermann, S., Lang, W., Beckmann, M.W., et al. (2007) Patients’ Attitudes to Totally Implantable Venous Access Port Systems for Gynecological or Breast Malignancies. European Journal of Surgical Oncology, 33, 39-43. &lt;br&gt;https://doi.org/10.1016/j.ejso.2006.08.003</mixed-citation></ref></ref-list></back></article>